Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
As pain is such a heterogeneous indication, significant opportunities remain for a variety of different and more effective non-opioid treatment options to be developed.
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Today, GE HealthCare (Nasdaq: GEHC) and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. ...
A version of this story appeared in Volume 103, Issue 11 Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising ...
Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results